CHRISTIE BALLANTYNE to Drug Monitoring
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Drug Monitoring.
Connection Strength
0.285
-
Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2021 08; 35(4):793-800.
Score: 0.172
-
Effect of Evolocumab on Coronary?Plaque Composition. J Am Coll Cardiol. 2018 10 23; 72(17):2012-2021.
Score: 0.036
-
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). Am Heart J. 2016 Dec; 182:89-96.
Score: 0.031
-
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). Am Heart J. 2016 Jun; 176:83-92.
Score: 0.030
-
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006 Mar; 259(3):247-58.
Score: 0.015